The animal model market has seen considerable growth due to a variety of factors.
• The animal model market has seen strong growth in recent years. It will grow from $1.92 billion in 2024 to $2.09 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%.
This growth is attributed to the rising use of animal models in biomedical research, higher investments in drug development and discovery, a focus on precision medicine, and the widespread application of animal models in healthcare.
The animal model market is expected to maintain its strong growth trajectory in upcoming years.
• The animal model market is expected to grow strongly, reaching $2.92 billion by 2029 at a CAGR of 8.8%.
This growth is driven by advancements in genetic engineering, a focus on personalized medicine, rising chronic diseases, the need for effective vaccines and therapeutics, and higher biomedical research investment. Key trends include the rising use of animal models in drug discovery, the need for humanized mice models, and the high growth due to the adoption of animal models in biomedical research.
The rising investment in pharmaceutical research and development is expected to propel the growth of the animal model market. Animal models play a crucial role in pharmaceutical R&D by simulating human diseases and drug responses. As R&D investments increase, animal models aid in the development of new drugs and therapies. For example, in June 2023, the European Federation of Pharmaceutical Industries and Associations reported a significant increase in R&D spending, totaling €44,500 million in 2022. This growing investment in R&D is driving the animal model market.
The animal model market covered in this report is segmented –
1) By Animal Type: Mice, Rat, Guinea Pigs, Rabbits, Hamsters, Other Animal Types
2) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Embryonic Stem Cell Injection, Nuclear Transfer, Other Technologies
3) By Application: Drug Discovery And Development, Basic Research, Other Applications
4) By End User: Research Institutes, Educational Institutes, Pharmaceutical Companies, Contract Research Organizations
Subsegments:
1) By Mice: Inbred Mice, Outbred Mice, Knockout Mice, Transgenic Mice
2) By Rat: Inbred Rats, Outbred Rats, Transgenic Rats, Knockout Rats
3) By Guinea Pigs: Standard Guinea Pigs, Immunodeficient Guinea Pigs
4) By Rabbits: New Zealand White Rabbits, Dutch Belted Rabbits, Other Rabbit Breeds
5) By Hamsters: Syrian Hamsters, Chinese Hamsters
6) By Other Animal Types: Non-Human Primates (Monkeys, Chimpanzees), Dogs, Pigs, Sheep, Ferrets, Other Small Animals (Ferrets, Gerbils)
In the animal model market, companies are advancing preclinical studies with the development of triple-immunodeficient animal models. For example, in January 2024, Charles River Laboratories introduced NCG mouse strains, designed for oncology and immunology research. These mice lack critical immune system components, making them ideal for studying human diseases and developing new therapies.
Major companies operating in the animal model market are:
• Eurofins Scientific SE
• Charles River Laboratories International Inc.
• Pharmaron Beijing Co Ltd.
• Inotiv Inc.
• Biocytogen
• Taconic Biosciences Incorporation
• Cyagen Biosciences
• Trans Genic Incorporation
• Crown Bioscience Incorporation
• Harbor BioMed
• PharmaLegacy
• PsychoGenics
• Biomere Biomedical Research Models Inc.
• Genoway S.A
• Alloy Therapeutics
• Janvier Labs
• Hera Biolabs
• Ozgene Pty Ltd.
• Transposagen Biopharmaceuticals Inc.
• KMT Hepatech Inc.
• AniLocus Inc.
• BioXpert
• Harlan Sprague Dawley Inc.
North America was the largest region in the animal model market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal model market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.